Stock HNSA HANSA BIOPHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

News Hansa Biopharma AB

Equities

HNSA

SE0002148817

Market Closed - Nasdaq Stockholm
Other stock markets
 17:00:00 25/06/2024 BST 		5-day change 1st Jan Change
46.6 SEK -4.12% Intraday chart for Hansa Biopharma AB +3.60% +77.86%
05-31 Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial MT
05-31 Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm
AQ
Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial
MT
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
AQ
Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial
CI
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
AQ
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
AQ
Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting
CI
Correction, Hansa Biopharma, increase in number of shares and votes
AQ
Correction: Hansa Biopharma: increase in number of shares and votes
PU
Hansa Biopharma: increase in number of shares and votes
AQ
Hansa Biopharma Q1 - Improved European launch support
AQ
Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
Hansa Biopharma interim report January-March 2024
AQ
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hansa Biopharma Approves SEK372 Million Directed Share Issue
MT
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)
AQ
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024
CI
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports
AQ
Hansa Biopharma Hires New CFO
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HNSA Stock
  4. News Hansa Biopharma AB